About the Role
2026-04-30 11:23:00
finance.yahoo.com
With a market cap of $159.9 billion, Gilead Sciences, Inc. (GILD) is a global biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs across areas such as HIV, liver diseases, cancer, and infectious diseases. It offers a broad portfolio of treatments and collaborates with multiple organizations to advance innovative therapies worldwide.
Shares of the Foster City, California-based company have underperformed the broader market over the past 52 weeks. GILD stock has increased 22.6% over this time frame, while the broader S&P 500 Index ($SPX) has gained 28.4%. However, the stock has risen 6.4% on a YTD basis, outpacing SPX’s 4.5% return.
More News from Barchart
Looking closer, shares of Gilead Sciences have outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 2.6% rise over the past 52 weeks.
Shares of Gilead Sciences climbed 5.8% following its Q4 2025 results on Feb. 10, driven by 5% revenue growth to $7.9 billion, solid adjusted EPS of $1.86, and strong underlying demand with full-year product sales excluding Veklury up 4% to $28 billion, led by Biktarvy (up 7% to $14.3 billion) and Descovy (up 31% to $2.8 billion). Investors also liked the upbeat 2026 setup, including management’s mention of the successful U.S. launch of Yeztugo, continued growth in HIV and liver disease, and upcoming potential launches such as two cancer therapies and an additional HIV option.
Guidance reinforced that optimism, with 2026 product sales expected at $29.6 billion – $30 billion ($29.0 billion – $29.4 billion excluding Veklury), and adjusted EPS guided to $8.45 – $8.85.
For the fiscal year ending in December 2026, analysts expect GILD’s adjusted EPS to grow 5.8% year-over-year to $8.62. The company’s earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters while missing on another occasion.
Among the 32 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 22 “Strong Buy” ratings, two “Moderate Buys,” and eight “Holds.”
On Apr. 8, Truist Financial analyst Gregory Renza raised the price target on Gilead Sciences to $155, maintaining a “Buy” rating.
The Ledger Nano X Crypto Wallet Signer takes security even further by keeping your private keys isolated from any connected system. With 8,725 global ratings and a 4.3 out of 5 star rating, users value its ease of use and powerful security features. 400+ bought in the past month shows strong demand. Available now with a 20% discount for $79.00.
Support Techcratic
Independent. Uninfluenced. Performance-focused.
Whether it’s Tech Flix, 30 Second Tech, App Zone, or deep
Techcratic analysis, every piece is built for readers who want clarity over noise.
If you value that, you can support Techcratic below. Thank you.
Bitcoin Support
Scan the QR code with your crypto wallet app
or copy and paste the below address:
bc1qlszw7elx2qahjwvaryh0tkgg8y68enw30gpvge
Please read the Privacy and Security Disclaimer.
Disclaimer: As an Amazon Associate, Techcratic may earn from qualifying purchases.